CIRSE Registry for SIR-Spheres Therapy

Status Completed

Clinical Trial Summary

The administration of SIR-Spheres microspheres (yttrium-90 resin microspheres) is a form of selective internal radiation therapy (SIRT) for the treatment of patients with primary and secondary liver tumours. The primary objective is to observe the real-life clinical application of radioembolisation with SIR-Spheres and the impact of the treatment in clinical practice. Secondary objectives are to observe safety and effectiveness of SIR-Spheres treatment in terms of adverse events, Overall Survival (OS), Progression-free survival (PFS), technical considerations, liver PFS and Quality of Life (QoL) + subgroup analyses

Clinical Trial Description

Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. Following administration, 94% of the radiation is delivered in 11 days. Previous reports on the safety and efficacy of yttrium-90 resin microspheres for the treatment of primary and secondary liver tumours are very promising. In order to further improve the understanding of this therapy in its true clinical setting, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the CIRSE Registry for SIR-Spheres Therapy (CIRT), a phase 4 observational study that aims to collect robust data on the real-life clinical practice of radioembolisation with SIR-Spheres microspheres. Further, using the quality of life questionnaire QLQ-C30 with its hepatocellular carcinoma module (developed and verified by the European Organisation of Research and Treatment of Cancer (EORTC)), CIRT aims to collect data on the quality of life of patients treated with SIR-Spheres microspheres. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02305459
Study type	Observational [Patient Registry]
Source	Cardiovascular and Interventional Radiological Society of Europe
Contact
Status	Completed
Phase
Start date	November 2014
Completion date	January 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Recruiting	`NCT04443322` - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )	N/A
Terminated	`NCT00791544` - Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Completed	`NCT02424955` - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation	N/A
Completed	`NCT03775863` - AFP Model and Liver Transplantation.
Not yet recruiting	`NCT04825470` - Liver Transplantation for Unresectable GIST Liver Metastases	N/A
Recruiting	`NCT06144385` - A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma	Phase 1
Completed	`NCT01717729` - Hepatocellular Carcinoma Treated With Iodine-125 Implantation	Phase 3
Completed	`NCT03178409` - Combined HCC-MFCCC	N/A
Recruiting	`NCT01380392` - The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma	N/A
Withdrawn	`NCT01744639` - Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation	N/A
Completed	`NCT01482442` - SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma	Phase 3
Active, not recruiting	`NCT01272557` - Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial	Phase 2
Completed	`NCT00328770` - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma	Phase 2/Phase 3
Completed	`NCT05681234` - Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma	N/A
Terminated	`NCT00767234` - Permission to Collect Blood Over Time for Research	N/A
Recruiting	`NCT04288323` - Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CIRSE Registry for SIR-Spheres Therapy — CIRT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms